Three-year real-world effectiveness, treatment persistence, and planned discontinuation of anti-calcitonin gene-related peptide monoclonal antibodies for migraine prevention: a single-center cohort from Japan

Frontiers in Neurology 2026 Open access

Read full text
Authors: Hideyo Kasai, Taro Yasumoto, Shota Kosuge, Ayako Osanai, Keita Mizuma, Akinori Futamura, Takeshi Kuroda, Kenjiro Ono, Hidetomo Murakami
DOI: 10.3389/fneur.2026.1827022
Cited by: 1
References: 25

Abstract

Introduction: Long-term real-world evidence beyond 24 months for anti-calcitonin gene-related peptide (CGRP) monoclonal antibodies is scarce, particularly regarding treatment persistence and planned discontinuation after goal attainment. Methods: We conducted a single-center retrospective study of consecutive patients aged ≥15 years who initiated galcanezumab or fremanezumab (monthly/quarterly) between May 2021 and June 2022. Specifically, patients aged ≥15 years with episodic migraine (EM;

Fields of Study & Subjects

Migraine and Headache Studies Nicotinic Acetylcholine Receptors Study Traumatic Brain Injury Research

Publication details

Journal / source
Frontiers in Neurology
Publisher
Frontiers Media SA
Volume
17
Pages
1827022–1827022
Publication date
13 May 2026
Language
EN